Silvan Tuerkcan
Stock Analyst at Citizens
(4.31)
# 423
Out of 5,136 analysts
184
Total ratings
47.78%
Success rate
19.31%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $56.89 | +51.17% | 17 | Dec 23, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $35 → $57 | $37.18 | +53.31% | 15 | Dec 11, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $6.31 | +58.48% | 5 | Nov 20, 2025 | |
| ENGN enGene Holdings | Maintains: Market Outperform | $18 → $21 | $9.10 | +130.77% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $12.02 | +74.71% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $5.04 | +58.73% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $12.13 | +81.37% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $1.62 | +270.37% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $16.11 | +111.05% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $37.03 | +21.52% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $50 | $45.23 | +10.55% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $5.81 | +158.18% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $4.31 | +39.21% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $6.31 | +42.63% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $14.77 | +712.46% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.83 | +828.96% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $5.65 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $1.57 | +154.78% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $8.07 | +160.22% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.78 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $4.27 | +40.52% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $130.33 | +114.84% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $12.62 | +42.63% | 1 | Jan 26, 2023 |
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $56.89
Upside: +51.17%
Terns Pharmaceuticals
Dec 11, 2025
Maintains: Market Outperform
Price Target: $35 → $57
Current: $37.18
Upside: +53.31%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $6.31
Upside: +58.48%
enGene Holdings
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $9.10
Upside: +130.77%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $12.02
Upside: +74.71%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $5.04
Upside: +58.73%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $12.13
Upside: +81.37%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $1.62
Upside: +270.37%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $16.11
Upside: +111.05%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $37.03
Upside: +21.52%
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $45.23
Upside: +10.55%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $5.81
Upside: +158.18%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $4.31
Upside: +39.21%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $6.31
Upside: +42.63%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $14.77
Upside: +712.46%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.83
Upside: +828.96%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $5.65
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $1.57
Upside: +154.78%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $8.07
Upside: +160.22%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.78
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $4.27
Upside: +40.52%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $130.33
Upside: +114.84%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $12.62
Upside: +42.63%